| 查看: 422 | 回复: 0 | |||
[交流]
有钱买股，没钱研发
|
|
夏季美国最大的头条之一就是NantKwest公司首次公开募股就完成2亿美元的市值，公司市值达25亿美元，接下来的日子，股价一直下滑，目前，已经下滑三分之一，该公司没有注入钱到研发，而是用5000万美元回购股票。 NantKwest ($NK), an oncology biotech in Patrick Soon-Shiong's constellation of companies, made headlines over the summer when it pulled off a $200 million IPO that valued it at more than $2.5 billion. But the company's share value has slipped by nearly a third in the ensuing months, and instead of pouring money into developing its self-described breakthrough medicines, management has taken the uncommon tack of laying out $50 million to buy back stock. NantKwest's 'growth prospects and long-term strategy are not reflected in the company's current stock price,' Soon-Shiong said in a statement, and its buyback program 'demonstrates our confidence in the strength of our business, our strong conviction in our long-term growth prospects and our commitment to delivering shareholder value.' The move is an unusual one for loss-taking, research-focused biotech companies, which generally use their IPO proceeds to invest in R&D in hopes of coming up with clinical data that might boost their market value. That $50 million figure well outstrips the $3.9 million NantKwest spent on research in the third quarter. Cellectis ($CLLS), which has a similar market cap, spends nearly three times that per quarter, as does Adaptimmune ($ADAP), a U.K. oncology biotech with a valuation about half the size of NantKwest's. But Soon-Shiong has never been much for biotech convention. The entrepreneur, who made a fortune selling Abraxis Bioscience to Celgene ($CELG) for $2.9 billion, operates more than about a dozen companies under his NantWorks umbrella. Most are focused on oncology, and each deals almost exclusively with its sibling companies. NantCell, developing a once-failed Amgen ($AMGN) treatment for cancer, has raised more than $175 million and teamed up with frequent Soon-Shiong partner Sorrento Therapeutics ($SRNE) in immuno-oncology. Then there's NantiBody, a joint venture with Sorrento; NantPharma, at work on a next-generation version of Celgene's Abraxane; NantBioScience, developing nanoparticle cancer treatments; and NantHealth, a tech firm offering what Soon-Shiong calls 'the Google of genome mapping.' [ Last edited by 凌宇雷池 on 2015-11-16 at 18:07 ] |
回复此楼» 猜你喜欢
医药口服制剂辅料应用
已经有0人回复
-
全新推出Tguide®靶向递送方案，突破99% T细胞转染效率
已经有1人回复
-
药物学论文润色/翻译怎么收费?
已经有253人回复
-
Mal-LN29-LNP-mRNA 试剂盒：自带Mal基团，一盒实现抗体筛选与体内靶向验证
已经有0人回复
-
自由偶联 | 脾脏靶向：抗体偶联空载LNP试剂盒
已经有0人回复
-
SM-102 试剂盒，告别纳米制备仪！
已经有0人回复
-
2026年辅料登记预告
已经有1人回复
-
SPguide®：小鼠体内脾脏转染的一键解决方案
已经有0人回复
-
高效肺靶向RNA转染，加速肺部RNA药物开发
已经有2人回复
-
二糖的糖脂，合成后sephadex LH-20分离不出来，求助
已经有1人回复